BLP-25 liposomal vaccine: A promising potential therapy in non-small-cell lung cancer

Expert Review of Respiratory Medicine

Volumn 2, Issue 1, 2008, Pages 37-45

  Powell, Erin ^a   Chow, Laura Q M ^a  

^a OTTAWA REGIONAL CANCER CENTRE   (Canada)

Author keywords

Clinical trial; Immunotherapy; L BLP25; Liposomal vaccine; MUC1; Non small cell lung cancer; Stimuvax

Indexed keywords

ANTINEOPLASTIC AGENT; AS 02B; BELAGENPUMATUCEL; BLP 25; CANCER VACCINE; CYCLOPHOSPHAMIDE; GAMMA INTERFERON; IMMUNOGLOBULIN G2A ANTIBODY; IMMUNOLOGIC AGENT; INTERLEUKIN 1; INTERLEUKIN 2; LIPOSOME; LUCANIX; MELANOMA ANTIGEN 3; MONOCLONAL ANTIBODY CD28; MUCIN 1; PLACEBO; STIMUVAX; TARMOGEN; TUMOR NECROSIS FACTOR ALPHA; VACCINE;

ADJUVANT THERAPY; ANTIBODY PRODUCTION; ARTICLE; BREAST ADENOCARCINOMA; CANCER CHEMOTHERAPY; CANCER GENE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; FATIGUE; FEVER; FLU LIKE SYNDROME; HEADACHE; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; INJECTION SITE ERYTHEMA; INJECTION SITE REACTION; LIPOSOMAL GENE DELIVERY SYSTEM; LOW DRUG DOSE; LUNG CANCER; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MORTALITY; MULTIPLE CYCLE TREATMENT; NAUSEA; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NORTH AMERICA; PANCREAS CANCER; PHARMACODYNAMICS; PNEUMONIA; PROSTATE CANCER; QUALITY OF LIFE; SINGLE DRUG DOSE; TH1 CELL; TH2 CELL; UNSPECIFIED SIDE EFFECT;

EID: 47649084543     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/17476348.2.1.37     Document Type: Article

References (46)

1. National Cancer Institute of Canada. Canadian Cancer Statistics 2007. Toronto, ON, Canada (2007).
2. American Cancer Society. Cancer facts and figures 2007. Atlant, GA, USA (2007).
3. The International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatinum-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N. Engl. J. Med. 350(4), 351-360 (2004).
4. Winton T, Livingston R, Johnson D et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N. Engl. J. Med. 352(25), 2589-2597 (2005).
5. Roth J, Fossella F, Komaki R et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J. Natl. Cancer Inst. 86(9), 673-680 (1994).
6. Rosell R, Gomez-Codina J, Camps C et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N. Engl. J. Med. 330(3), 153-158 (1994).
7. Depierre A, Milleron B, Moro-Sibilot D et al. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (Except TIM), II, IIIa non-small-cell lung cancer. J. Clin. Oncol. 20(1), 247-253 (2002).
8. Belani CP, Choy H, Bonomi P et al. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol. J. Clin. Oncol. 23(25), 5883-5891 (2005).
9. DiUman R, Seagrean S, Propert K et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in Stage III Non-small-cell lung cancer. N. Engl. J Med. 323(14), 940-945 (1990).
10. Sause W, Kolesar P. Taylor S et al. Final results of phase III trial in regionally advanced unresectable non-small-cell lung cancer. Chest 117(2), 358-365 (2000).
11. Furuse K, Fukuoka M, Kawahara M et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J. Clin. Oncol. 17(9), 2692-2699 (1999).
12. Okawara G, Mackay JA, Evans WK, Ung YC and the Lung Cancer Disease Site Group. Management of unresected stage III non-small-cell lung cancer: a clinical practice guideline. Evidence-based series #7-3 (Version 2.2005): Section 1. A. Program of Cancer Care Ontario. Current report date: January 2006.
13. Mountain CF. A new international staging system for lung cancer. Chest 89(4 Suppl.), S225-S233 (1986).
14. Non-small-cell lung cancer Collaborative Group. Chemotherapy in non-small-cell lung cancer: a meta-analysis using updated date on individual patients from 52 randomized clinical trials. BMJ 311(7010), 899-909 (1995).
15. Cochrane Lung Cancer Group. Chemotherapy for non-small-cell lung cancer. Cochrane Database Syst. Rev. 4, (2004). Date of most recent substantive update: February 1, 2000.
16. Johnson D, Fehrenbacher L, Novotny W et al. Randomized Phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J. Clin. Oncol. 22(11), 2184-2191 (2004).
17. Herbst R, O'Neill V, Fehrenbacher L et al. Phase II Study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non-small-cell lung cancer.J. Clin. Oncol. 25(30), 1-8 (2007).
18. Palmer M, Parker J, Modi S et al. Phase I study of the BLP25 (MUC1 peptide) liposomal vaccine for active specific immunotherapy in stage IIIB/IV non-small-cell lung cancer. Clin. Lung Cancer 3(1), 49-57 (2001)
19. Hege K, Carbone D. Lung cancer vaccines and gene therapy. Lung Cancer 41, S103-S113 (2003).
20. Liu M, Acres B, Balloul JM et al. Gene-based vaccines and immunotherapeutics. Proc. Natl Acad. Sci. USA. 101(2), 14567-14571 (2004).
21. Nemunaitis J, Nemunaitis J. A review of vaccine clinical trials for non-small-cell lung cancer. Expert Opin. Biol. Ther. 7(1), 89-102 (2007).
22. Nemunaitis J, Murray N. Immune-modulating vaccines in non-small-cell lung-cancer.J. Thorac. Oncol. 1(7), 756-761 (2006).
23. Salgia. R, Lynch T, Skarin A et al. Vaccination with irradiated autologous tumour cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor Immunity in some patients with metastatic non-small-cell lung cancer. J. Clin. Oncol. 21(4), 624-630 (2003).
24. Scholl S, Squiban P, Bizouarne N et al. Metastatic breast tumour regression following treatment by a gene-modified vaccinia virus expressing MUC1 and 1L2. J. Biomed. Biotechnol. 3, 194-201 (2003).
25. Lu Y, Kawakami S, Yamashita F, Hasida M. Development of an antigen-presenting cell-targeted DNA vaccine against melanoma by mannosylated liposomes. Biomaterials 28(21), 3255-3262 (2007).
26. Kotera Y, Fontenot J, Pecher G et al. Humoral immunity against a tandem repeat epitope of human mucin MUC1 in sera from breast, pancreatic and colon cancer patients. Cancer Res. 54, 2856-2860 (1994).
27. Gendler S, Lancaster C, Taylor-Papadimitriou J et al. Molecular cloning and expression of human tumour-associated polymorphic epithelial mucin. J. Biol. Chem. 265, 15286-15293 (1990).
28. Ding L, Lalani EN, Reddish M et al. Immunogenicity of synthetic peptides related to the core peptide sequence encoded by the human MUC1 mucin gene: effect of immunization on the growth of murine mammary adenocarcinoma cells transfected with the human MUC1 gene. Cancer Immunol. Immunother. 36, 9-17 (1993).
29. Ho S, Niehans G, Lyftogt C et al. Heterogeneity of mucin gene expression in normal and neoplastic tissue. Cancer Res. 53, 641-651 (1993).
30. Ren J, Agata N, Chen D et al Human MUC1. carcinoma-associated protein confers resistance to genotoxic anticancer agents. Cancer Cell. 5, 163-175 (2004).
31. Agrawal B, Krantz M, Reddish M, Longeneckder M. Cancer-associated MUC1 inhibits human T-cell proliferation, which is reversible by IL-2. Nat. Med. 4(1), 43-49 (1998).
32. Sangha R, Butts C. L-BLP25: a peptide vaccine strategy in non-small-cell lung cancer. Clin. Cancer Res. 13(15 Suppl.), S4652-S4654 (2007).
33. Pantuck A, van Ophoven A, Giditz; B et al. Phase I trial of antigen-specific gene therapy using a recombinant vaccinia virus encoding MUC-1 and 11-2 in MUC-1-positive patients with advanced prostate cancer.J Immunother. 27(3), 240-253 (2004).
34. Squiban P, Velu T, Mennecier B et al. NWA-MUCI-IL2 vaccine immunotherapy for advanced non-small-cell. lung cancer (NSCLC): interim Phase II data. J. Clin. Oncol. Annual meeting proceedings (Post-Meeting Edition) 22(Suppl. 145), 2544 (2004).
35. Guan H, Budzynski W, Koganty R et al. Liposomal formulations of synthetic MUC1 peptides: effects of encapsulation versus surface display of peptides on immune responses. Bioconjugate Chem. 9, 451-458 (1998).
36. Okada M, Kita Y, Nakajima T et al. Evaluation of a novel vaccine (HVJ-liposome/HSP65 DNA + IL-12 DNA) against tuberculosis using the cynomolgus monkey model of TB. Vaccine 25(16), 2990-2993 (2007).
37. Samuel J, Budzynski W, Reddish M et al. Immunogenicity and antitumor activity of a liposomal MUCI peptide-based vaccine. Int. J. Cancer 75, 295-302 (1998).
38. Butts C, Murray N, Maksymiuk A et al. Randomized Phase II3 trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J. Clin. Oncol. 23(27), 6674-6681 (2005)
39. Bass K, Mastrangelo M. Immunopotentiation with low-dose cyclophosphamide in the active specific immunotherapy of cancer. Cancer Immunol. Immunother. 47,1-12 (1998).
40. Goldberg S. Physiology Made Ridiculously Simple. MedMaster Inc., Miami, FL, USA 72-77 (1995).
41. North S, Butts C. Vaccination with BLP25 liposome vaccine to treat non-small cell lung and prostate cancers. Expert Rev. Vaccines 4(3) 249-257 (2005).
42. Biomira Inc. Investigator's Brochure for Stimuvax™ (BLP25 Liposome Vaccine; L-BLP25) for immunotherapy of epithelial carcinomas. Unpublished. Edmonton, Alberta, Canada. Release date: January 30, 2006.
43. Murray N, Butts C, Maksymijuk A, Marshall E, Goss G, Soulieres D. A liposomal MUCI vaccine for treatment of non-small-cell lung cancer (NSCLC); updated survival results from patients with Stage IIIB disease. 2005 ASCO Annual Meeting, Orlando, FL, USA, 13-17 May, 2005 (Abstract 7037).
44. Rochlitz C, Figlin R, Squiban P et al. Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUCI as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer J. Gene Med. 5, 690-699 (2003).
45. Nemunaitis J, Dillman RO, Schwarzenberger PO et al. Phase II study of Belagenpumatucel-L, a transforming growth factor β-2 antisense gene-modified allogeneic tumour cell vaccine in non-small-cell lung cancer (NSCLC). J. Clin. Oncol. 24(29) 4721-4730 (2006).
46. Brichard V, Lejeune D. GSK's antigen-specific cancer immunotherapy program: Pilot results leading to Phase III clinical development. Vaccine 25(Suppl. 2), B61-B71 (2007).